2. UroToday Home
  3. Actionable Clinical Data
  4. NMIBC with CIS: Evidence, Practice & Emerging Research
  5. Articles
  6. Conferences

AUA 2026

AUA 2026

Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy

Details
  • ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.
  • ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.
  • Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS.
Las Vegas, Nevada (UroToday.com) -- Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting.

Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer

Details
  • First Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezūm™1
  • Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer2
Las Vegas, Nevada (UroToday.com) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment.

AUA 2026: Prostate Cancer Screening, Detection, and Surveillance - Guidelines versus Real-World Practice versus Recent Evidence

Details

(UroToday.com) The 2026 AUA annual meeting featured the International Prostate Forum and a presentation by Dr. Badar Mian discussing guidelines, real-world practice, and recent evidence for prostate cancer screening, detection, and surveillance. Dr. Mian started his presentation by highlighting where each key organization in the United States sits on the PSA screening spectrum and what makes their guidance distinctive:

AUA 2026: Locally Advanced and Recurrent Prostate Cancer Updates - Management of Biochemical Recurrence in 2026

Details

(UroToday.com) The 2026 AUA annual meeting featured the International Prostate Forum and a presentation by Dr. Karen Hoffman discussing the management of biochemical recurrence in 2026. Dr. Hoffman began by revisiting the historical evidence supporting adjuvant radiation therapy following radical prostatectomy. Landmark randomized trials, including SWOG 8794, EORTC 22911, and ARO 96-02, demonstrated that adjuvant radiation improved PSA failure outcomes, reduced locoregional recurrence, and decreased the need for subsequent salvage therapy in men with pT3 disease or positive surgical margins:

AUA 2026: Localized Treatment - The Daily Triage of Grade Group 2 Prostate Cancer

Details

(UroToday.com) The 2026 AUA annual meeting featured the International Prostate Forum and a presentation by Dr. John Davis discussing the daily triage of Grade Group 2 prostate cancer. Dr. Davis started his presentation highlighting that there has been an evolving scope of active surveillance over the decades:

AUA 2026: Role of Lymph Node Dissection at the Time of Radical Prostatectomy

Details

(UroToday.com) The 2026 AUA annual meeting featured the International Prostate Forum and a presentation by Dr. Tarik Esen discussing the role of lymph node dissection at the time of radical prostatectomy. In 2023, the EAU guidelines stated that for intermediate risk prostate cancer, urologists should perform an extended pelvic lymph node dissection based on predicted lymph node invasion (validated nomogram).

AUA 2026: State-of-the-Art Lecture: Contemporary Perioperative Non-Opioid Pain Management Strategies

Details

(UroToday.com)  Monday morning’s plenary featured Dr. Boyd Viers of Mayo Clinic, who delivered a data-driven, clinically actionable lecture on reducing opioid prescribing in urological surgery. Framing his opening with characteristic directness, Dr. Viers established the core premise of his talk: “We are the prescribers. We are the solution.” He presented data from national registries, multi-institutional collaboratives, and his own institution’s five-year journey from prescribing all patients five opioid tablets to zero. In a call to action, he offered every urologist in the room a practical framework they could implement the following morning.

AUA 2026: Impact of Increased H-1B Visa Cost on the Urology Workforce: A Simulation-Based Projection of the Urologist Shortage by 2035

Details

(UroToday.com)  On the final day of the 2026 American Urological Association (AUA) Annual Meeting, Dr. Hachem Ziadeh from University Hospitals Cleveland Medical Center presented a simulation-based workforce analysis evaluating the projected impact of increased H-1B visa costs on the future U.S. urology workforce. The study examined how reductions in international medical graduate (IMG) recruitment may further exacerbate the already growing national shortage of practicing urologists.

AUA 2026: Dehydrated Human Amniotic Membrane for Early Return of Erectile Function After Robotic Radical Prostatectomy: A 10-Year Journey and Lessons Learned

Details

(UroToday.com)  Dr. Shirin Razdan from the Miami Robotic Surgery at the Comprehensive Urologic Surgery Institute presented a retrospective analysis evaluating the use of dehydrated human amniotic membrane (dHAM) as a neurovascular bundle wrap during bilateral, nerve-sparing robot-assisted radical prostatectomy (nsRALP) to facilitate earlier return of erectile function, continence recovery, and potency following surgery.

AUA 2026: Extraperitoneal Robot-Assisted Radical Prostatectomy with the Hugo™ RAS System: 100 Consecutive Cases, 1-Year Follow-up and Surgical Learning Curve Evaluation

Details

(UroToday.com)  HugoTM robotic-assisted surgery (RAS) system is a new robotic device developed by Medtronic. With the recent introduction of this robotic platform, there is certainly interest and questions regarding its feasibility, ergonomics, and capabilities. One area of interest concerns the utilization of this RAS system for extraperitoneal robot-assisted radical prostatectomy (eRARP); however, research into its use for RARP is currently lacking. As such, Dr. Giovanni Filomena presented his prospective, single-center study on the perioperative, functional, and ergonomic outcomes of eRARPs using the HugoTM RAS system up to a 1-year follow-up.

AUA 2026: Cohesion-Interfacial Enhanced Adhesive Hydrogel Patch for Hemostasis and Tissue Injury Repair After Partial Nephrectomy

Details

(UroToday.com) Dr. Yan Li presented a novel adhesive hydrogel patch designed for suture-free renal wound closure following partial nephrectomy. Conventional renorrhaphy techniques may prolong ischemia time and contribute to tissue injury and postoperative bleeding. The investigators developed a cohesion-interfacial enhanced hydrogel patch intended to provide rapid hemostasis while maintaining strong adhesion in wet surgical environments.

AUA 2026: Cancer Extent and Cellularity but not Inflammatory Density are associated with MRI-Invisible Prostate Cancer on AI-Based Digital Pathology Deep Learning Models

Details

(UroToday.com) Dr. Ramin Nateghi presented a podium session investigating the biologic and histopathologic characteristics associated with MRI-visible and MRI-invisible clinically significant prostate cancer (csPCa) using artificial intelligence (AI)-based digital pathology analysis. While multiparametric MRI has substantially improved prostate cancer detection and risk stratification, clinically significant tumors may still evade detection despite contemporary imaging protocols. The investigators sought to better understand the tissue-level features that contribute to false-negative MRI findings.

AUA 2026: Alvimopan in Patients Undergoing Radical Cystectomy and Urinary Diversion on a Standardized Enhanced Recovery After Surgery Protocol: A Randomized, Double-Blind, Placebo-Controlled Trial

Details

(UroToday.com) At the 2026 American Urological Association (AUA) Annual Meeting, Dr. Kendrick Yim from the Moffitt Cancer Center presented results from a randomized, double-blind, placebo-controlled trial evaluating the role of alvimopan, a peripheral μ-opioid receptor antagonist, in patients undergoing radical cystectomy with urinary diversion within a standardized Enhanced Recovery After Surgery (ERAS) protocol.

AUA 2026: Contemporary Practice Patterns Among Urologic Oncologists for the Assessment of Women’s Sexual and Pelvic Health After Radical Cystectomy

Details

(UroToday.com) Radical cystectomy (RC) in women often involves the removal of gynecologic organs, which can increase the risk of female sexual dysfunction (FSD) and pelvic organ prolapse (POP). Even though there are guidelines for screening and management of these complications, practices still vary quite a bit between surgeons. This study looked at current practice patterns among Society of Urologic Oncology (SUO) members performing female RC, with a focus on how often surgeons screen for FSD and POP and what surgical techniques they commonly use.

New PSMAddition Data Show 58% Lower Risk of PSA Progression with Pluvicto® in Metastatic Hormone-Sensitive Prostate Cancer

Details
  • More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC alone
  • Deep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weeks
  • sNDA filed in US, China and Japan; decisions expected H2 2026
Las Vegas, Nevada (UroToday.com) -- Novartis announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.

AUA 2026: Radiographic Progression-free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial

Details

(UroToday.com) The 2026 American Urologic Association (AUA) Annual Meeting featured an important presentation by Dr. Neeraj Agarwal evaluating whether radiographic progression-free survival (rPFS) is a clinically meaningful surrogate endpoint for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), using individual patient-level data from the phase III TALAPRO-2 trial.

AUA 2026: Duration of Treatment Suspension Among All Randomized Patients in EMBARK

Details

(UroToday.com) The 2026 American Urological Association (AUA) Annual Meeting featured a podium presentation by Dr. Neal D. Shore reporting a post hoc exploratory analysis from the phase 3 EMBARK trial evaluating the duration of treatment suspension among all randomized patients with high-risk biochemically recurrent prostate cancer.

AUA 2026: Safety of Rucaparib versus Docetaxel or Second-generation Androgen Receptor Pathway Inhibitor Therapy for Patients with Metastatic Castration-resistant Prostate Cancer and a BRCA mutation in TRITON3

Details

(UroToday.com) The 2026 American Urologic Association Annual Meeting featured a presentation by Dr. Alan H. Bryce evaluating the safety and tolerability of rucaparib compared with physician’s choice of docetaxel or a second-generation androgen receptor pathway inhibitor (ARPI) in patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) enrolled in the phase III TRITON3 trial.

AUA 2026: Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Reconstructed Individual Patient Data Analysis of the PEACE-3 Trial

Details

(UroToday.com) The 2026 American Urologic Association (AUA) Annual Meeting featured an innovative presentation by Dr. Soichiro Yoshida evaluating the time-dependent overall survival benefit of enzalutamide plus radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) using reconstructed individual patient data (rIPD) from the EORTC 1333/PEACE-3 trial.

AUA 2026: Early Experience with the Da Vinci 5 System: Surgical Efficiency and Functional Recovery Using a Force-Feedback Robotic Platform

Details

(UroToday.com) The Da Vinci 5 (DV5) robotic platform introduces several new features, including force feedback technology, improved ergonomics, and enhanced 3D visualization, which may improve surgical precision and reduce tissue trauma during robotic surgery. In this presentation, Dr. Neeraja Tillu discussed the group’s early experience using the DV5 system for robot-assisted radical prostatectomy (RARP), with a focus on surgical efficiency, oncologic safety, and early functional outcomes.